[前列腺特异性抗原]
[Prostate specific antigen].
作者信息
Koutani A, Lechevallier E, Coulange C
机构信息
Service d'Urologie B, Hôpital Avicenne, Rabat, Maroc.
出版信息
Ann Urol (Paris). 1996;30(5):257-61.
PMID:8975592
Abstract
Prostate specific antigen is the "gold standard" prostate tissue marker. Based on a reviews of the literature, we present the metabolism, method and lassay clinical use for diagnosis, staging and prostate cancer as well as for monitoring response to treatment. The authors also discuss some situations able to increase the level of this marker.
摘要
前列腺特异性抗原是前列腺组织的“金标准”标志物。基于对文献的综述，我们阐述了前列腺特异性抗原在前列腺癌诊断、分期以及监测治疗反应方面的代谢、检测方法和临床应用。作者还讨论了一些可能导致该标志物水平升高的情况。
相似文献
1
[Prostate specific antigen].[前列腺特异性抗原]
Ann Urol (Paris). 1996;30(5):257-61.
2
Early-stage prostate cancer, PSA screening rates decline.早期前列腺癌，前列腺特异抗原筛查率下降。
Cancer. 2016 Mar 15;122(6):825. doi: 10.1002/cncr.29930.
3
4
Age-specific reference ranges for prostate-specific antigen.
JAMA. 1994 Mar 9;271(10):746-7.
5
Clinical significance of prostate specific antigen for early stage prostate cancer detection.前列腺特异性抗原在早期前列腺癌检测中的临床意义。
Jpn J Clin Oncol. 1994 Jun;24(3):160-5.
6
Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?关于：美国前列腺癌的前列腺特异性抗原时代已经结束：过去20年发生了什么？
J Urol. 2005 Sep;174(3):1155; author reply 1155-6. doi: 10.1016/s0022-5347(01)68555-0.
7
Prostate-specific antigen, clinical use and staging: an overview.前列腺特异性抗原、临床应用及分期：概述
Br J Urol. 1997 Mar;79 Suppl 1:53-60. doi: 10.1111/j.1464-410x.1997.tb00802.x.
8
[PSA 2010--the beginning of a new era in early detection of prostate cancer].[2010年前列腺特异性抗原——前列腺癌早期检测新时代的开端]
Urologe A. 2006 Sep;45 Suppl 4:127-33. doi: 10.1007/s00120-006-1173-9.
9
Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers.理解关于前列腺特异性抗原的复杂信息：癌症生物标志物评估中的偏差
J Urol. 2007 Feb;177(2):426-7. doi: 10.1016/j.juro.2006.11.009.
Zotero 插件